Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.58 |
| ▸ | ACE | P12821 | 3/20 | 0.53 |
| ▸ | CPA1 | P15085 | 3/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7102694 | 1.00 | MME (0.58) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL7104122 | 0.92 | MMP8 (0.55) | MMEACECPA1ACE2POLB | |
| SCHEMBL7099381 | 0.92 | MMP8 (0.55) | MMEACECPA1ACE2POLB | |
| SCHEMBL7098301 | 0.92 | ADAMTS5 (0.54) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL7104216 | 0.92 | SMN1; SMN2 (0.52) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL7102264 | 0.92 | MMP8 (0.58) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL7102259 | 0.92 | MMP8 (0.58) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL7099462 | 0.89 | KMT2A (0.60) | KMT2AMEN1 | |
| SCHEMBL7099460 | 0.89 | KMT2A (0.60) | KMT2AMEN1 | |
| SCHEMBL7098082 | 0.89 | MME (0.55) | MMEACECPA1ACE2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140818-B1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMA INC (US) | 2003-09-10 | — | — | EP | claimed |
| US-6329550-B1 | FOR THERAPY OF EMPHYSEMA, OSTEOPOROSIS, RHEUMATOID ARTHRITIS AND NEOPLASTIC DISEASES | AVENTIS PHARMACEUTICALS INC. | 2001-12-11 | — | — | US | claimed |
| EP-1140818-B1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMA INC (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6329550-B1 | FOR THERAPY OF EMPHYSEMA, OSTEOPOROSIS, RHEUMATOID ARTHRITIS AND NEOPLASTIC DISEASES | AVENTIS PHARMACEUTICALS INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1140818-A1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | Aventis Pharmaceuticals Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040552-A1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |